Ceritinib

• Ceritinib is an anaplastic lymphoma kinase (ALK) inhibitor approved for treating ALK-positive metastatic non-small cell lung cancer (NSCLC).
• It works by blocking the activity of the ALK protein, which is often overactive in certain cancer cells, thereby inhibiting tumor growth.
• Common side effects include gastrointestinal issues, fatigue, and elevated liver enzymes, while serious warnings involve liver toxicity, lung inflammation, and heart rate changes.
• Dosage and administration require careful consideration, typically involving oral intake with food, and close monitoring for adverse reactions is essential.

What is Ceritinib and How It Works in Cancer?

Ceritinib is an oral medication classified as a tyrosine kinase inhibitor (TKI). It is specifically designed to target and inhibit the activity of the anaplastic lymphoma kinase (ALK) fusion protein. This protein is a key driver in a subset of non-small cell lung cancer (NSCLC) cases, where a genetic rearrangement leads to its abnormal activation.

How does Ceritinib work in cancer? Ceritinib functions by selectively binding to and inhibiting the ALK receptor tyrosine kinase. In ALK-positive cancers, this protein is constitutively active, promoting uncontrolled cell growth and survival. By blocking ALK, Ceritinib disrupts the signaling pathways that cancer cells rely on for proliferation and survival, leading to a reduction in tumor size and progression. This targeted approach helps to spare healthy cells to a greater extent than traditional chemotherapy, though side effects can still occur.

Ceritinib: Indications, Dosage, and Administration

Ceritinib is used for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC). This indication applies to patients who have progressed on or are intolerant to crizotinib, or as a first-line treatment for newly diagnosed ALK-positive metastatic NSCLC. The presence of the ALK rearrangement must be confirmed by an FDA-approved test prior to initiating therapy.

Regarding Ceritinib drug information and dosage, the recommended starting dose is typically 450 mg taken orally once daily with food. It is crucial to administer Ceritinib with food to enhance its absorption and reduce gastrointestinal side effects. Dose modifications may be necessary based on individual patient tolerance and the occurrence of adverse reactions. Regular monitoring of liver function, blood glucose, and other parameters is essential throughout the treatment period to manage potential toxicities effectively. Patients should be advised not to crush, chew, or split the capsules.

Ceritinib Side Effects, Warnings, and Precautions

Patients undergoing treatment with Ceritinib side effects and warnings should be aware of a range of potential adverse reactions. Common side effects include gastrointestinal disturbances such as diarrhea, nausea, vomiting, and abdominal pain. Other frequently reported side effects are fatigue, elevated liver enzymes, decreased appetite, and anemia. These effects often require supportive care and, in some cases, dose reduction or temporary interruption of treatment.

More serious warnings associated with Ceritinib include severe liver toxicity (hepatotoxicity), interstitial lung disease (ILD) or pneumonitis, and bradycardia (slow heart rate). Patients should be monitored for symptoms of ILD, such as new or worsening shortness of breath, cough, or fever. Regular monitoring of liver function tests and electrocardiograms (ECGs) is recommended to detect and manage these serious adverse events promptly. Additionally, Ceritinib can cause hyperglycemia, so blood glucose levels should be monitored, especially in patients with diabetes or those at risk of developing it. Visual disturbances have also been reported, necessitating ophthalmologic evaluation if symptoms occur. It is crucial for patients to report any new or worsening symptoms to their healthcare provider immediately.